Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
7.45 ^USD	+7.19%		-4.73%	-39.13%

May. 09	Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	CI
May. 07	Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024

PULSE BIOSCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)

December 19, 2019 at 04:05 pm EST

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

(b)

On December 17, 2019, Thomas J. Fogarty, M.D., resigned from the Board of Directors (the "Board") of Pulse Biosciences, Inc. (the "Company") and all committees of the Board for personal reasons. The resignation of Mr. Fogarty is effective immediately and is not the result of any disagreement with the Company relating to the Company's operations, policies or practices. Dr. Fogarty's service and contributions to the Company are greatly appreciated.

--------------------------------------------------------------------------------

Latest news about Pulse Biosciences, Inc.

Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System	May. 09	CI
Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024	May. 07
Pulse Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Sector Update: Health Care Stocks Slide Late Afternoon	Apr. 01	MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	Apr. 01	MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 08	MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	Mar. 08	MT
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	Mar. 08	CI
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	Feb. 14	CI
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	Jan. 02	MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	Jan. 02	MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	Jan. 02	CI
Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter	Dec. 20	CI
Pulse Biosciences Insider Bought Shares Worth $843,504, According to a Recent SEC Filing	Dec. 14	MT
Pulse Biosciences Insider Bought Shares Worth $1,117,085, According to a Recent SEC Filing	Dec. 01	MT
Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan	Nov. 27	DJ
Pulse Biosciences Cleared to Start Catheter Ablation Feasibility Trial; Set to File Application for Cardiac Clamp; Shares Rise	Nov. 27	MT
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Nov. 21	MT
Sector Update: Health Care	Nov. 21	MT
Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review	Nov. 21	DJ
Pulse Biosciences Files Premarket Notification to FDA for CellFX nsPFA Percutaneous Electrode	Nov. 21	MT
Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode	Nov. 21	CI

Chart Pulse Biosciences, Inc.

Duration

Period

More charts

Company Profile

Pulse Biosciences, Inc. is a bioelectric medicine company. The Companyâs proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Companyâs Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-06 - Annual General Meeting

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
PULSE BIOSCIENCES, INC.	-39.13%	411M
THERMO FISHER SCIENTIFIC	+11.73%	226B
DANAHER CORPORATION	+9.53%	188B
INTUITIVE SURGICAL, INC.	+14.63%	137B
BOSTON SCIENTIFIC CORPORATION	+27.47%	108B
SIEMENS HEALTHINEERS AG	-0.04%	63.19B
EDWARDS LIFESCIENCES CORPORATION	+13.73%	52.26B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.86%	51B
AGILENT TECHNOLOGIES, INC.	+7.72%	43.89B
GE HEALTHCARE TECHNOLOGIES INC.	+7.86%	38.07B

Other Advanced Medical Equipment & Technology